Skip navigation

Canlyniadau chwilio am the

Yn dangos 496 i 510 o 2073 canlyniadau

HCPC gender, ethnicity and disability pay gaps report 2024

Annual reports on the gender and ethnicity pay gaps, with this year marking the first publication of the disability pay gap.

Education annual data set: 2018-19 academic year

Snapshot of outcomes related to the HCPC’s education function for the 2018-19 academic year

Commonly asked record-keeping questions, answered

Katherine Timms, Head of Policy and Standards at the HCPC, answers the most common questions we receive from registrants about record keeping

Protected function - hearing aid dispensers

We regulate hearing aid dispensers on the basis of their professional title and also their protected function.

Multiple Registrant Search

Search the Register for up to 100 professionals at a time

HCPC response to DHSC healthcare regulation consultation

As we move forward with the wider programme of regulatory reform, we welcome this consultation to consider how the powers to introduce and remove professions from regulation might be used in the future.

HCPC responds to the Government’s regulatory reform consultation

“An important step towards modernising and reforming professional regulation”

Chiropodists, podiatrists and hearing aid dispensers renewal window closing soon

The deadline for chiropodists, podiatrists and hearing aid dispensers to complete their registration renewal is fast approaching

Understanding the Duty of Candour- new resources available for you

New materials outline what candour means and what it looks like in practice.

Higher and Degree Apprenticeships Review Report 2019-20

Snapshot of outcomes related to higher and gegree apprenticeships for the academic year 2019-20

Legal Assessor

Legal Assessors are legally qualified and provide advice to panels of the HCPC’s statutory committees and Council on questions of law

Reclassification of Gabapentin and Pregabalin

From midnight on 1st April 2019, gabapentin and pregabalin will be reclassified as Schedule 3 controlled drugs, under the Misuse of Drugs Regulations (2001), and Class C of the Misuse of Drugs Act (1971)